Generation and production of engineered antibodiesSergey M Kipriyanov
Affimed Therapeutics AG, Technologiepark, Im Neuenheimer Feld 582, D 69120 Heidelberg, Germany
Mol Biotechnol 26:39-60. 2004
....
- Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies
Sergey M Kipriyanov
Recombinant Antibody Research Group, German Cancer Research Center DKFZ, Im Neuenheimer Feld 280, D 69120 Heidelberg, Germany
J Mol Biol 330:99-111. 2003
..The structural parameters influencing the formation of functional bispecific single-chain antibodies are indicated and ways of making relatively stable bispecific molecules are proposed...
- Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody
Fabrice Le Gall
Affimed Therapeutics AG, Im Neuenheimer Feld 582, D-69120 Heidelberg, Germany
Protein Eng Des Sel 17:357-66. 2004
....
- Immunosuppressive properties of anti-CD3 single-chain Fv and diabody
Fabrice Le Gall
Affimed Therapeutics AG, Im Neuenheimer Feld 582, D-69120 Heidelberg, Germany
J Immunol Methods 285:111-27. 2004
..The anti-CD3 diabody may provide a potent immunosuppressive drug with low toxicity and immunogenicity...
- Generation of bispecific and tandem diabodies
Sergey M Kipriyanov
Affimed Therapeutics AG, Ladenburg, Germany
Methods Mol Biol 178:317-31. 2002
- Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma
Sergey M Kipriyanov
Affimed Therapeutics, Heidelberg, Germany
J Immunol 169:137-44. 2002
..These data clearly demonstrate the synergistic effect of small recombinant bispecific molecules recruiting different populations of human effector cells to the same tumor target...
- Recent advances in the generation of bispecific antibodies for tumor immunotherapy
Sergey M Kipriyanov
Affimed Therapeutics AG, Im Neuenheimer Feld 582, D 69120 Heidelberg, Germany
Curr Opin Drug Discov Devel 7:233-42. 2004
..This review briefly summarizes major trends in the development of bispecific antibodies for tumor therapy, and describes a rationale for the generation of novel recombinant molecules...
- Generation and characterization of bispecific tandem diabodies for tumor therapy
Sergey M Kipriyanov
Affimed Therapeutics AG, Heidelberg, Germany
Methods Mol Biol 207:323-33. 2003
- Generation of antibody molecules through antibody engineering
Sergey M Kipriyanov
Affimed Therapeutics AG, Heidelberg, Germany
Methods Mol Biol 207:3-25. 2003
- Antibody Discovery and Preclinical Development--SRI's International Meeting. 24-26 February 2003, San Diego, CA, USA
Sergey M Kipriyanov
Affirmed Therapeutics AG, Technologiepark, Im Neuenheimer Feld 582, D-69120 Heidelberg, Germany
IDrugs 6:327-30. 2003
- High-level periplasmic expression and purification of scFvs
Sergey M Kipriyanov
Affimed Therapeutics AG, Ladenburg, Germany
Methods Mol Biol 178:333-41. 2002
- Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells
Uwe Reusch
Affimed Therapeutics, Heidelberg, Germany
Int J Cancer 112:509-18. 2004
..5 pM. These data demonstrate that the tetravalent CD19xCD3 tanDb might be a promising tool for the immunotherapy of human B-cell leukemias and lymphomas...
- Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma
Jana Schlenzka
University Hospital for Internal Medicine, Department of Hematology/Oncology, Heidelberg University Medical School, Heidelberg, Germany
Anticancer Drugs 15:915-9. 2004
..c. tumor. These results suggest that a combination treatment with recombinant diabodies and angiogenesis inhibition represents a useful approach in cancer therapy...
